Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 8/20 | 0.46 |
| ▸ | PPARG | P37231 | 5/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 4/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14360873 | 0.93 | ABCB1 (0.42) | PPARAPPARGABCB1MEN1KMT2A | |
| SCHEMBL5430183 | 0.84 | PPARG (0.41) | PPARAPPARGABCB1MEN1KMT2A | |
| SCHEMBL5437303 | 0.80 | PPARA (0.54) | PPARAPPARGDRD3LTA4H | |
| SCHEMBL5423669 | 0.73 | PPARA (0.54) | PPARAPPARGMEN1KMT2A | |
| SCHEMBL5441860 | 0.72 | PPARA (0.56) | PPARAPPARG | |
| SCHEMBL5434311 | 0.72 | PPARA (0.52) | PPARAPPARGDRD3 | |
| SCHEMBL5434312 | 0.71 | PPARA (0.56) | PPARAPPARGMEN1KMT2A | |
| SCHEMBL5428115 | 0.71 | PPARA (0.56) | PPARAPPARG | |
| SCHEMBL5428793 | 0.71 | PPARA (0.52) | PPARAPPARGDRD3 | |
| SCHEMBL10623622 | 0.70 | ABCB1 (0.57) | ABCB1KMT2ADRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005049589-A2 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF HYPERLIPIDEMIA, DIABETES, OBESITY AND SIMILAR DISEASES | CADILA HEALTHCARE LIMITED (IN) | 2005-06-02 | — | — | WO | claimed |
| US-20070275956-A1 | Novel Heterocyclic Compounds | CADILA HEALTHCARE LIMITED (IN) | 2007-11-29 | — | — | US | disclosed |
| WO-2005049589-A2 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF HYPERLIPIDEMIA, DIABETES, OBESITY AND SIMILAR DISEASES | CADILA HEALTHCARE LIMITED (IN) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275956-A1 | Novel Heterocyclic Compounds | CYP46A1, DHCR7, NPC1L1 | PPARA 990/4885PPARG 615/4885ABCB1 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.